JP2008531665A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531665A5
JP2008531665A5 JP2007557572A JP2007557572A JP2008531665A5 JP 2008531665 A5 JP2008531665 A5 JP 2008531665A5 JP 2007557572 A JP2007557572 A JP 2007557572A JP 2007557572 A JP2007557572 A JP 2007557572A JP 2008531665 A5 JP2008531665 A5 JP 2008531665A5
Authority
JP
Japan
Prior art keywords
effective amount
pharmaceutically acceptable
pharmaceutically effective
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007557572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531665A (ja
Filing date
Publication date
Priority claimed from GBGB0504103.3A external-priority patent/GB0504103D0/en
Application filed filed Critical
Publication of JP2008531665A publication Critical patent/JP2008531665A/ja
Publication of JP2008531665A5 publication Critical patent/JP2008531665A5/ja
Pending legal-status Critical Current

Links

JP2007557572A 2005-02-28 2006-02-27 パーキンソン病の治療における2−(2−ニトロ−4−トリフルオロメチルベンゾイル)−1,3−シクロヘキサンジオンの使用 Pending JP2008531665A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method
PCT/GB2006/000684 WO2006090177A1 (en) 2005-02-28 2006-02-27 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE

Publications (2)

Publication Number Publication Date
JP2008531665A JP2008531665A (ja) 2008-08-14
JP2008531665A5 true JP2008531665A5 (https=) 2009-03-12

Family

ID=34430351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007557572A Pending JP2008531665A (ja) 2005-02-28 2006-02-27 パーキンソン病の治療における2−(2−ニトロ−4−トリフルオロメチルベンゾイル)−1,3−シクロヘキサンジオンの使用

Country Status (17)

Country Link
US (1) US20090326072A1 (https=)
EP (1) EP1853241B1 (https=)
JP (1) JP2008531665A (https=)
CN (1) CN101163466B (https=)
AT (1) ATE524171T1 (https=)
AU (1) AU2006217650B2 (https=)
BR (1) BRPI0609177A2 (https=)
CA (1) CA2598517A1 (https=)
DK (1) DK1853241T3 (https=)
ES (1) ES2374761T3 (https=)
GB (1) GB0504103D0 (https=)
IL (1) IL185410A0 (https=)
MX (1) MX2007010480A (https=)
PT (1) PT1853241E (https=)
RU (1) RU2420272C2 (https=)
WO (1) WO2006090177A1 (https=)
ZA (1) ZA200707486B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2011004769A (es) * 2008-11-06 2011-11-29 Biotie Therapies Inc Tratamiento de sindrome de pierna sin reposo y alteraciones del sueño.
EP2723320B1 (en) * 2011-06-23 2016-01-13 Swedish Orphan Biovitrum International AB Liquid pharmaceutical composition comprising nitisinone
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
EA201890346A1 (ru) * 2015-07-29 2018-08-31 Такеда Гмбх Ингибитор pdf4 для лечения диабетической нефропатии
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof
TW202543611A (zh) * 2024-03-27 2025-11-16 美商費斯製藥有限公司 Hpd抑制劑組成物及使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones
EP0591275B1 (en) * 1991-06-24 1999-03-31 Zeneca Limited Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of tyrosinaemia and pharmaceutical compositions
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20050288187A1 (en) * 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
WO2005007096A2 (en) * 2003-07-11 2005-01-27 Merck & Co., Inc. Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
BRPI0621959A2 (pt) * 2006-08-18 2011-12-27 Syngenta Ltd usos de pelo menos um composto capaz de inibir 4-hidroxifenilpiruvato dioxigenase, e de um composto ou uma composiÇço, kit, e, composiÇço farmacÊutica
MX2011004769A (es) * 2008-11-06 2011-11-29 Biotie Therapies Inc Tratamiento de sindrome de pierna sin reposo y alteraciones del sueño.

Similar Documents

Publication Publication Date Title
IL259851A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
WO2007131005A3 (en) Use of organic compounds
JP2009541489A5 (https=)
JP2012520883A5 (https=)
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
JP2006526031A5 (https=)
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
JP2013541514A5 (https=)
JP2011527299A5 (https=)
JP2009545527A5 (https=)
JP2008302206A5 (https=)
JP2011522035A5 (https=)
IL192150A (en) Use of 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophyll} ethyl-1,3-propanadiol, or its acceptable medical salt or hydrate, for the preparation or treatment of inflammatory bowel disease
JP2008531665A5 (https=)
JP2009537554A5 (https=)
JP2009535370A5 (https=)
WO2008053446A3 (en) Benzoxazepine compounds, their preparation and use
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
JP2005536503A5 (https=)
JP2004532828A5 (https=)
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
CN115916350A (zh) Akt抑制剂的单位剂量组合物
JP2008513426A5 (https=)
JP2010527354A5 (https=)
JP2008513427A5 (https=)